KIT and gastrointestinal stromal tumor: Recently, enhancer domains of the KIT gene have been shown to be targetable by BET bromodomain inhibition in gastrointestinal stromal tumors, thus defining therapeutic vulnerability and the clinical strategy for targeting oncogenic kinases by the new generation of epigenetic drugs.